GLP-1s & Cancer Risk: Unpacking the Latest Research & Patient Safety

Last Updated: JUNE 2024

Over 1.7 million GLP-1 receptor agonist prescriptions were filled in the US in March 2024 alone, marking a 400% increase since early 2020, according to data from analytics firm Trilliant Health. This dramatic surge underscores the transformative impact of medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) on metabolic health. Yet, with widespread adoption comes intense scrutiny, particularly concerning long-term safety. One persistent shadow looming over GLP-1 RAs has been the specter of cancer, specifically thyroid cancer, an association rooted in preclinical animal studies and echoed in regulatory warnings. However, a growing body of real-world epidemiological data is now offering a clearer, often reassuring, picture, while simultaneously revealing intriguing new signals, including a potential protective effect against colon cancer.

Thyroid Cancer: Unpacking the FDA's Caution

The concern linking GLP-1 RAs to thyroid cancer primarily stems from early rodent studies, which observed an increase in C-cell hyperplasia and medullary thyroid carcinoma (MTC) in rats and mice administered high doses of these compounds. MTC is a rare form of thyroid cancer originating from parafollicular C-cells, which produce calcitonin. This specific finding led the U.S. Food and Drug Administration (FDA) to include a black box warning on GLP-1 RA labels, advising against their use in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

This regulatory posture, while prudent given the preclinical data, has often overshadowed the crucial biological distinction: rodents possess a higher density of thyroid C-cells and a different calcitonin physiology compared to humans. The mechanism observed in rodents, involving direct C-cell proliferation, has not been consistently replicated or observed in human trials. This discrepancy is a foundational element in understanding why human data has largely diverged from initial animal models.

Epidemiological Data: Dispelling Common Thyroid Cancer Fears

The most common types of thyroid cancer in humans are papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC), which originate from thyroid follicular cells. These are distinctly different from MTC. Decades of human clinical trial data and real-world observational studies involving hundreds of thousands, if not millions, of patient-years of exposure to GLP-1 RAs have consistently failed to demonstrate an increased risk of these common thyroid cancers.

A comprehensive white paper titled "Evaluating Thyroid Cancer Risk After GLP-1 Receptor Agonist Administration," published by the Clayman Thyroid Center in 2024, meticulously reviewed the existing evidence. Their conclusion was unequivocal:

"There was no convincing evidence that GLP-1 RAs cause papillary, follicular, or Oncocytic thyroid cancers. The overall risk for these common thyroid cancers in GLP-1 RA-treated populations does not appear to exceed background rates observed in the general population."

This sentiment has been echoed across numerous large-scale analyses. For instance, a meta-analysis published in The BMJ in 2023, encompassing data from multiple randomized controlled trials and observational studies, found no statistically significant association between GLP-1 RA use and an increased risk of thyroid cancer overall, nor specifically for papillary or follicular types. Another extensive study published in JAMA Internal Medicine in 2023, analyzing data from over 1.6 million patients, similarly concluded that GLP-1 RAs were not associated with an elevated risk of overall thyroid cancer, including papillary thyroid cancer.

The "Endocrine Connections" journal, in a 2025 review titled "Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?", examined the very question that has fueled much public anxiety. While acknowledging the theoretical concerns, the authors concluded that "human data from more than 15 years of clinical experience, along with extensive observational databases (2024–2025) and ongoing registries, continue to show no clear signal for thyroid cancer risk above background rates in treated populations for the most common forms of thyroid cancer."

Medullary Thyroid Cancer (MTC): The Persistent, Yet Unsubstantiated, Warning

Despite the reassuring data regarding common thyroid cancers, the theoretical risk of MTC remains the core of the FDA's black box warning. However, even for MTC, human evidence remains elusive. MTC is an extremely rare cancer, accounting for only 1-2% of all thyroid cancers. Its rarity makes detecting a subtle increase in incidence particularly challenging, even in very large studies. To date, clinical trials and real-world data have not reported a statistically significant increase in MTC cases among GLP-1 RA users compared to control groups.

The prevailing scientific consensus is that the observed rodent mechanism does not directly translate to humans. While vigilance is warranted, the current absence of human signal, after extensive exposure, strongly suggests that the MTC risk in humans is either negligible or non-existent in the vast majority of patients.

To summarize the current understanding of GLP-1 RAs and thyroid cancer risk:

Thyroid Cancer Type	Origin Cells	GLP-1 RA Association (Human Data)	Regulatory Posture / Preclinical Basis
Papillary Thyroid Carcinoma (PTC)	Follicular cells	No increased risk. Numerous large epidemiological studies show no association above background rates.	Not linked to rodent findings. No specific FDA warning for PTC.
Follicular Thyroid Carcinoma (FTC)	Follicular cells	No increased risk. Consistent with PTC, no association found in human data.	Not linked to rodent findings. No specific FDA warning for FTC.
Medullary Thyroid Carcinoma (MTC)	Parafollicular C-cells	No clear signal. Extremely rare, no statistically significant increase observed in human clinical trials or large observational studies to date.	FDA black box warning based on rodent studies (C-cell hyperplasia/MTC). Mechanism likely rodent-specific.

Beyond Thyroid: A Glimmer of Protection Against Colon Cancer?

While the focus has largely been on disproving thyroid cancer links, emerging data points to a potentially beneficial, albeit preliminary, association with other cancer types. Specifically, a growing body of research suggests that GLP-1 RAs may be associated with a reduced risk of colorectal cancer (CRC).

A recent cohort study